Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2026-06-02 16:30:02 ET · period of report 2026-06-01 · accession 0001193125-26-253601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 16:30 | 2026-06-01 | SNDX | Metzger Michael A | CEO, Dir | S - Sale | $18.99 | -6,847 | 484.8K | -1% | -$130.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | S | D | 6,847 | $18.99 | 484,843 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. |